Search Results
Sep 25, 2025, 14:01 ET U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
by 38% versus ET. Among patients with ESR1-mutated MBC, Inluriyo significantly improved progression-free survival (PFS) versus fulvestrant or exemestane, with a median PFS of 5.5 months vs 3.8 months (HR=0.62 [95% CI: 0.46-0.82]); p-value=0.0008. Inluriyo is a treatment for ER+, HER2–,
More news about: Eli Lilly and Company
Sep 25, 2025, 09:37 ET The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
after at least one anthracycline- or taxane-containing chemotherapy regimen. The phase III study data showed that UTD1 plus capecitabine achieved both PFS and OS benefits versus capecitabine for heavily pretreated MBC patients, and the results were orally presented twice at ASCO annual meetings and published
More news about: Biostar Pharma, Inc.
Sep 24, 2025, 13:38 ET ARIS MINING REPORTS SAFE RECOVERY OF ALL WORKERS AT SEGOVIA PARTNER MINE
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Sep 24, 2025, 06:15 ET Uranium Energy Corp Files Fiscal 2025 Annual Report
Commenced: Metallurgical test work significantly advanced, bulk solvent extraction and yellowcake precipitation completed and initiated a pre-feasibility study ("PFS") for the world-class, high-grade Roughrider project in Saskatchewan, Canada, in the prolific Athabasca
More news about: Uranium Energy Corp
Sep 23, 2025, 13:26 ET ARIS MINING CONFIRMS INCIDENT AT AN EXTERNAL MINE PARTNER OPERATION AT SEGOVIA
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Sep 23, 2025, 04:57 ET Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) as assessed by the Blinded Independent Central Review (BICR) compared with T-DM1. Currently, Kelun-Biotech has initiated an open, multi-center
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 22, 2025, 22:56 ET Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA; Final Phase III Results of Cadonilimab as First-Line Therapy for Advanced Gastric Cancer to Be Published as an Oral Presentation
study, HARMONi-6, met its primary endpoint of progression-free survival (PFS), as confirmed by the Independent Data Monitoring Committee (IDMC). The results showed statistically significant and clinically meaningful improvements in PFS for ivonescimab plus chemotherapy compared to tislelizumab plus chemotherapy.
More news about: Akeso, Inc.
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
its primary endpoint of progression-free survival (PFS) according to the Blinded Independent Review Committee (BIRC) and its key secondary endpoint of time to next intervention (TTNI) at the second pre-specified interim analysis. The primary endpoint, PFS per BIRC, was statistically significant and clinically
More news about: Servier Pharmaceuticals
Sep 18, 2025, 21:39 ET 2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment
CAR-T–naïve patients, ORR and CR/sCR rates were 98.9% and 88.4%, respectively. Among 109 patients who received Eque-cel, the median progression-free survival (PFS) was 30.5 months, extending to 35.9 months in CAR-T–naïve patients. Median overall survival (OS) was not reached. Minimal residual disease (MRD) negativity
More news about: IASO Bio
Sep 17, 2025, 07:32 ET Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars
Food and Drug Administration (FDA) has approved Bosaya™ (denosumab-kyqq) 60 mg/mL injection for subcutaneous use in a single dose prefilled syringe (PFS), and Aukelso™ (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial, biosimilars of Prolia® and Xgeva® respectively.
More news about: Biocon Biologics
Sep 15, 2025, 20:57 ET NEW PACIFIC FILES FORM 40-F ANNUAL REPORT
Company; inferred, indicated or measured mineral resources or mineral reserves on the Company's projects, including, but not limited to, the Silver Sand PFS Technical Report; the Carangas PEA Technical Report; the timing of receipt of permits and regulatory approvals; and estimates of the Company's revenues
More news about: New Pacific Metals Corp.
Sep 15, 2025, 08:00 ET Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
part plans to enroll 700 subjects across multiple countries/regions. The primary endpoint is overall survival (OS), with secondary endpoints including PFS, ORR, and safety. About NCT07044349 Study This study is a multi-national, open-label, randomized Phase II/III clinical trial of
More news about: Biostar Pharma, Inc.
Sep 12, 2025, 00:35 ET Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig
PD-1 inhibitor approved as first-line therapy for Chinese melanoma patients, demonstrated an ORR of 11% and a median progression-free survival (PFS) of 2.3 months in registrational studies that primarily enrolled patients with acral and mucosal melanoma. These data highlight a critical
More news about: Leads Biolabs
Sep 10, 2025, 17:31 ET TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight
American Society of Clinical Oncology (ASCO) data showing that sacituzumab tirumotecan significantly improved response rates, Progression-Free Survival (PFS), and Overall Survival (OS) vs. docetaxel in previously treated EGFR-mutant nonsquamous NSCLC.TROP2 ADCs in NSCLC Overview TROP2
More news about: DelveInsight Business Research, LLP
Sep 09, 2025, 09:00 ET Beacon Pointe Welcomes Three New Teams Across Three Key Regions
as this specific market continues to flourish. Partner and Managing Director, Scott Moser, CPA®, MST, PFS®, highlights, "Moser Wealth Advisors is opening a new chapter by joining Beacon Pointe Advisors. This union culminates an extensive search to find
More news about: Beacon Pointe Advisors
Sep 08, 2025, 19:33 ET DEFENSE METALS SETTLES DEBT WITH HCF INTERNATIONAL ADVISERS THROUGH EQUITY
Rupert, the closest major North American port to Asia. The Company recently completed a Preliminary Feasibility Study (PFS) that demonstrated robust economics for the project (refer to the Company's news releases of February 18, and April
More news about: Defense Metals Corp.
Sep 08, 2025, 08:30 ET ARIS MINING TO JOIN THE S&P/TSX COMPOSITE INDEX
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Sep 08, 2025, 08:00 ET IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
71% (5/7) To date, median progression free survival (PFS) and duration of response (DOR) has not been reached.33% ORR at DL1 (3/9); 3 confirmed partial responses (cPR),
More news about: IDEAYA Biosciences, Inc.
Sep 08, 2025, 07:00 ET Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current standard of care Translational data from multiple studies confirm pelareorep replication in CRC tumors and immune
More news about: Oncolytics Biotech® Inc.
Sep 08, 2025, 06:45 ET Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
of CLL. The primary endpoint is progression-free survival (PFS) as assessed by blinded independent review committee (IRC). Secondary endpoints include investigator and IRC assessed overall response rate (ORR), duration of response (DoR), and PFS, overall survival (OS), time to next treatment (TTNT), safety
More news about: Eli Lilly and Company
Sep 07, 2025, 12:00 ET IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
the confirmed ORR to 72.2% (13/18).Median PFS was 6.7 months across all lines of treatment at doses of IDE849 ≥2.4 mg/kg (n=86); median PFS was not yet reached (NR) in 2L patients (n=42).As of the cut-off date of
More news about: IDEAYA Biosciences, Inc.
Sep 07, 2025, 06:08 ET Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
Median PFS for ivonescimab vs. placebo plus chemotherapy was 6.8 months vs. 4.4 months, respectively. The PFS analysis was event driven and was conducted with 345 patients enrolled. There was a consistent observed benefit across pre-defined subgroups. In a longer-term follow-up of PFS, which included
More news about: Akeso, Inc.
Sep 07, 2025, 03:22 ET Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
endpoint of the study is progression-free survival (PFS) (using RECIST v1.1 guidelines**) as assessed by BICR. Secondary endpoints include overall survival, overall response rate, duration or response, progression-free survival after first subsequent therapy (PFS2) and intracranial PFS.6 About RYBREVANT®
More news about: Johnson & Johnson
Sep 06, 2025, 03:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
endpoint of the study is progression-free survival (PFS) (using RECIST v1.1 guidelines**) as assessed by BICR. Secondary endpoints include overall survival, overall response rate, duration or response, progression-free survival after first subsequent therapy (PFS2) and intracranial PFS.9 About RYBREVANT®
More news about: Johnson & Johnson
Sep 05, 2025, 07:30 ET ARIS MINING ANNOUNCES STEADY RAMP-UP AT SEGOVIA FOLLOWING SECOND MILL COMMISSIONING IN LATE JUNE
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation